Exicure Faces Nasdaq Delisting Risk After Equity Falls Below Minimum

Key Facts

In a move reflecting the financial hurdles facing micro-cap biotech firms, Exicure, Inc. has received a deficiency notice from Nasdaq regarding its stockholders' equity levels. According to reports, the company is no longer in compliance with the minimum $2.5 million equity requirement for continued listing on the Nasdaq Capital Market. This notification follows the company's failure to maintain the financial standards mandated by Nasdaq Listing Rule 5550(b)(1).

Companies within the biotechnology sector are facing heightened funding pressures, with many micro-caps struggling to meet listing requirements amid market volatility. Looking at industry peers, several firms in this space have recently resorted to reverse stock splits or capital raises to avoid delisting. Per market data, such regulatory notices typically trigger immediate selling pressure due to concerns over liquidity and the company's long-term viability.

At the close on June 12, 2026, XCUR shares stood at $2.78, having fluctuated between a high of $3.05 and a low of $2.71 during the session. Investors should watch for any upcoming announcements regarding the compliance plan Exicure must submit to Nasdaq. On the broader economic front, traders are looking toward U.S. inflation data on June 10, 2026, which could impact risk appetite for small-cap equities.